(Total Views: 791)
Posted On: 09/28/2017 9:25:35 AM
Post# of 113
IF P3 is successful then this stock could hit $80-100 per share (= Mcap $600-750M) thats not much for a Drug with $650 million potential.GL
Tonix's Tonmya Treats PTSD By Helping Sufferers Sleep Better ..Sep.27.17
https://seekingalpha.com/article/4109815-toni...eep-better
Summary
PTSD is a serious illness that has devastating symptoms. It affects 3.5% of American adults, or 8.6m individuals each year. The prevalence of PTSD is even higher among veterans.
The only FDA approved PTSD drug treatment, the SSRIs (selective serotonin reuptake inhibitors), failed to show efficacy in military-related PTSD and have serious side effects.
Tonix's Tonmya is being studied in HONOR, a phase 3 trial for treating military-related PTSD. Tonmya works by improving sleep quality and allowing the mind to heal itself.
This article focuses on PTSD and discusses how Tonmya can meet a very important unmet medical need.
Tonix's Tonmya Treats PTSD By Helping Sufferers Sleep Better ..Sep.27.17
https://seekingalpha.com/article/4109815-toni...eep-better
Summary
PTSD is a serious illness that has devastating symptoms. It affects 3.5% of American adults, or 8.6m individuals each year. The prevalence of PTSD is even higher among veterans.
The only FDA approved PTSD drug treatment, the SSRIs (selective serotonin reuptake inhibitors), failed to show efficacy in military-related PTSD and have serious side effects.
Tonix's Tonmya is being studied in HONOR, a phase 3 trial for treating military-related PTSD. Tonmya works by improving sleep quality and allowing the mind to heal itself.
This article focuses on PTSD and discusses how Tonmya can meet a very important unmet medical need.
(0)
(0)
